Modeling the economic value of a Chagas' disease therapeutic vaccine

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1293-1301

  Lee, Bruce Y ^a,b   Bacon, Kristina M ^a,b   Wateska, Angela R ^a,b   Bottazzi, Maria Elena ^c,d   Dumonteil, Eric ^e   Hotez, Peter J ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c SABIN VACCINE INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

Chagas' disease; Chagas' therapeutic vaccine; Cost effectiveness; Mexico; Trypanosoma cruzi

Indexed keywords

CHAGAS DISEASE VACCINE; TRYPANOSOMA CRUZI VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CARDIOMYOPATHY; CHAGAS DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; MEXICO; PROBABILITY; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VACCINATION;

CHAGAS DISEASE; HUMANS; IMMUNOTHERAPY, ACTIVE; LATIN AMERICA;

EID: 84867029445     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20966     Document Type: Article

References (39)

1. Parasites- American Trypanosomiasis (also known as Chagas Disease). Atlanta: Centers for Disease Control and Prevention, 2010.
2. Sustainable Development Department. The Millennium Development Goals in Latin America and the Caribbean: Progress, Priorities and IDB Support for Their Implementation. Washington, DC: Inter-American Development Bank, 2005.
3. Annex Table 3 Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002 In: The World Health Report 2004 -Changing History, ed. Geneva: World Health Organization, 2004.
4. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008; 2:e300; PMID:18820747; http://dx.doi.org/10.1371/journal. pntd.0000300.
5. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy - where do we stand after a hundred years? Prog Cardiovasc Dis 2010; 52:300-16; PMID:20109600; http://dx.doi.org/10.1016/j.pcad.2009.11.008.
6. Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years - a review. Mem Inst Oswaldo Cruz 2006; 101:345-54; PMID:16951802; http://dx.doi.org/10.1590/ S0074-02762006000400001.
7. Rassi A Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388-402; PMID:20399979; http://dx.doi.org/10.1016/S0140-6736(10)60061-X.
8. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' Disease in the United States. Clin Microbiol Rev 2011; 24:655-81; PMID:21976603; http://dx.doi.org/10.1128/CMR.00005-11.
9. Hotez P. Neglected diseases amid wealth in the United States and Europe. Health Aff (Millwood) 2009; 28:1720-5; PMID:19887412; http://dx.doi.org/10.1377/ hlthaff.28.6.1720.
10. Hotez PJ. Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2008; 2:e256; PMID:18575621; http://dx.doi.org/10. 1371/journal.pntd.0000256.
11. Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 2011; 7:1184-91; PMID:22048121; http://dx.doi.org/10.4161/hv.7.11.17016.
12. Vallejo M, Montenegro P, Reyes PA. [How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital]. Arch Cardiol Mex 2002; 72:129-37; PMID:12148332.
13. Franco-Paredes C, Bottazzi ME, Hotez PJ. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis 2009; 3:e470; PMID:19582139; http://dx.doi.org/10.1371/journal.pntd.0000470.
14. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526-9; PMID:9790423.
15. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407-13; PMID:8937280; http://dx.doi.org/10.1016/S0140-6736(96)04128-1.
16. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40:1-10; PMID:17486245; http://dx.doi.org/10.1590/S0037-86822007000100001.
17. Basombrío MA, Schofield CJ, Rojas CL, del Rey EC. A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans R Soc Trop Med Hyg 1998; 92:137-43; PMID:9764315; http://dx.doi.org/10.1016/S0035-9203(98) 90720-9.
18. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis 2009; 3:e488; PMID:19582142; http://dx.doi.org/10.1371/journal.pntd.0000488.
19. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, et al. Mother-to-child transmission of Chagas' disease in North America: why don't we do more? Matern Child Health J 2008; 12:283-6; PMID:17602289; http://dx.doi.org/10.1007/s10995-007-0246-8.
20. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 2010; 4:e916; PMID:21179503; http://dx.doi.org/10.1371/journal. pntd.0000916.
21. Sanchez-Burgos G, Mezquita-Vega RG, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Ouaissi A, et al. Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunol Med Microbiol 2007; 50:333-41; PMID:17521394; http://dx.doi.org/10.1111/j.1574-695X.2007.00251.x.
22. Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sánchez-Burgos G, Ramirez-Sierra MJ, et al. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine 2010; 28:7414-9; PMID:20850536; http://dx.doi.org/10.1016/j.vaccine.2010.08.104.
23. Hotez PJ, Dumonteil E, Heffernan MJ, Bottazzi ME. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas through mass drug administration and new vaccines for hookworm and Chagas disease. Adv Exp Med Biol 2012; In press.
24. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921-35; PMID:19538117; http://dx.doi.org/10.1586/erv.09.45.
25. Chongqing Jiachen Biotechnology Ltd. Therapeutic Hepatitis B Vaccine (Synthesized Peptide) in Treating Chronic Hepatitis B Patients. 2011.
26. Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, et al.; AIDS Clinical Trials Group A5187 Team. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010; 5:e10555; PMID:20479938; http://dx.doi.org/10.1371/journal.pone.0010555.
27. Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007; 16:491-511; PMID:17013993; http://dx.doi.org/10.1002/hec.1176.
28. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 2010; 28:2806-9; PMID:19782109; http://dx.doi.org/10.1016/j.vaccine.2009.09.047.
29. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007; 102(Suppl 1):75-85; PMID:17891282; http://dx.doi.org/10.1590/S0074-02762007005000093.
30. Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, González R, et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol 1985; 8:45-56; PMID:3997291; http://dx.doi.org/10.1016/0167-5273(85)90262-1.
31. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York, 1996.
32. Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, Martínez MF, et al. The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2008; 2:e336; PMID:19015725; http://dx.doi.org/10.1371/journal.pntd.0000336.
33. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:e69-75; PMID:20932171; http://dx.doi.org/10.1086/656917.
34. Frye JE, ed. International Drug Price Indicator Guide. Arlington: Mangement Sciences for Health, Inc., 2009.
35. The World Bank. GDP per capita (current US$). 2009.
36. Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 2005; 73:901-10; PMID:16282301.
37. Pinotti HW, Habr-Gama A, Cecconello I, Felix VN, Zilberstein B. The surgical treatment of megaesophagus and megacolon. Dig Dis 1993; 11:206-15; PMID:8222303; http://dx.doi.org/10.1159/000171413.
38. Rassi A Jr., Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001; 76:75-96; PMID:11175486.
39. World Health Organization. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva, 2004.